Esperion Q4 2022 Earnings Report
Key Takeaways
Esperion reported a Q4 2022 revenue of $18.8 million, driven by increased U.S. product and royalty revenue. The company also highlighted the successful completion of the CLEAR Outcomes trial and a 41% reduction in selling, general, and administrative expenses.
Total revenue for Q4 2022 was $18.8 million, a 22% increase compared to Q4 2021.
U.S. product revenue for Q4 2022 was $15.0 million, a 23% increase compared to Q4 2021.
Research and development expenses increased by 20% to $33.0 million due to accelerated CVOT costs.
Net losses decreased to $55.5 million, compared to $65.1 million for the same period in 2021.
Esperion
Esperion
Esperion Revenue by Segment
Forward Guidance
Esperion anticipates the CLEAR Outcomes data will improve clinical management for millions of patients and that NEXLETOL will deliver clinically meaningful reductions in hard endpoints.